1686TiP Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations

• DOI: 10.1016/j.annonc.2023.09.2633
• Publication Date: 2023-10-20T13:08:35Z
• Authors: T. Macarulla; F. Castet; M. Lobo de Mena; R. Garcia-Carbonero; E. Martinez de Ca...; A.J. Munoz Martin; R.A. Pazo Cid; B. Grana Suarez; J. Gallego Plazas; R. Alvarez; I.C. Ales Diaz; I. Gallego Jimenez; B. Laquente; M. Rodriguez; B. García Paredes; M.T. Cano Osuna; I. Ruiz de Mena; C. Fabregat-Franco; P. Espinosa Olarte; E. Aranda Aguilar
• Keywords: Olaparib; PALB2; PARP inhibitor